Voloridge Investment Management
BMRN icon

Voloridge Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Voloridge Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-444,890
Closed -$26.4M – 1026
2025
Q4 		$26.4M Sell
444,890
-156,156
-26% -$8.5M 0.09% 275
2025
Q3 		$32.6M Sell
601,046
-421,263
-41% -$24.1M 0.11% 225
2025
Q2 		$56.2M Buy
1,022,309
+868,188
+563% +$51.1M 0.21% 125
2025
Q1 		$10.9M Sell
154,121
-117,177
-43% -$7.88M 0.04% 547
2024
Q4 		$17.8M Buy
271,298
+222,958
+461% +$14.9M 0.06% 383
2024
Q3 		$3.4M Buy
48,340
+41,867
+647% +$3.5M 0.01% 857
2024
Q2 		$533K Buy
+6,473
New +$539K ﹤0.01% 1120
2023
Q1 		– Sell
-50,336
Closed -$5.21M – 1374
2022
Q4 		$5.21M Buy
+50,336
New +$4.73M 0.03% 625
2022
Q1 		– Sell
-3,849
Closed -$340K – 1378
2021
Q4 		$340K Buy
+3,849
New +$318K ﹤0.01% 1461
2021
Q3 		– Sell
-32,017
Closed -$2.67M – 1653
2021
Q2 		$2.67M Sell
32,017
-21,510
-40% -$1.71M 0.02% 880
2021
Q1 		$4.04M Buy
+53,527
New +$4.37M 0.03% 594
2020
Q4 		– Sell
-8,148
Closed -$620K – 1323
2020
Q3 		$620K Sell
8,148
-1,237
-13% -$125K 0.01% 1056
2020
Q2 		$1.16M Sell
9,385
-45,752
-83% -$4.55M 0.01% 797
2020
Q1 		$4.66M Buy
+55,137
New +$4.75M 0.13% 171
2016
Q2 		– Sell
-3,763
Closed -$310K – 302
2016
Q1 		$310K Buy
+3,763
New +$306K 0.01% 288
2015
Q4 		– Sell
-51,760
Closed -$5.45M – 195
2015
Q3 		$5.45M Sell
51,760
-103,321
-67% -$13.8M 0.26% 102
2015
Q2 		$21.2M Buy
155,081
+27,418
+21% +$3.4M 1.08% 21
2015
Q1 		$15.9M Buy
+127,663
New +$13.5M 0.77% 34

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Voloridge Investment Management's BMRN Position: Q1 2026 in Review

Voloridge Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 444,890 shares — an estimated $26.4M sold.

Voloridge Investment Management first reported a position in BMRN in Q1 2015 and held it in 18 quarters. The position peaked at $56.2M in Q2 2025. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Voloridge Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Voloridge Investment Management sold 444,890 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $26.4M.
  • Voloridge Investment Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 18 quarters.
  • Voloridge Investment Management's BioMarin Pharmaceuticals position peaked at $56.2M in Q2 2025.
  • 559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.